Zitat von Gast am 31. März 2026, 14:53 Uhr

[url=https://www.researchgate.net/scientific-contributions/Zoya-N-Demidenko-39445053]Zoya Demidenko[/url]: Scientist in Tumor Science
[url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPALLO%20ENTERPRISE%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMULTISERVICES%20L220000371890&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord]Zoya Demidenko[/url] is a distinguished researcher affiliated with the Unit of Cell Stress Science at Roswell Park Oncology Institute in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, building a robust base in clinical study.
Demidenko's academic output covers several key domains, including the PI3K/AKT/mTOR molecular pathway, cell cycle control, cell senescence, and malignancy biology. Currently, she has written over 46 peer-reviewed publications, which have garnered over 4,100 mentions — a testament to the impact of her findings.
One of her most significant achievements lies in understanding the processes of biological cell aging. Her work showed that when the cell cycle is halted while cellular expansion continues, cells enter senescence. Crucially, [url=https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/]Zoya Demidenko[/url] demonstrated that this transition can be inhibited by medication using agents such as mTOR inhibitors.
[url=https://moodylab.smhs.gwu.edu/lab-members]Zoya Demidenko[/url] has additionally contributed substantially to tumor management research, notably in the area of selective cell protection — a method designed to protecting non-cancerous cells from chemotherapy while leaving cancer cells exposed. This method carries major hope for diminishing the side effects of oncological therapy.
Across her scientific life, Demidenko has collaborated with prominent researchers internationally, including Dr. Mikhail Blagosklonny. Her publications can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
[31.03.2026 11:21] Папа: With an h-index of 33, [url=https://www.aging-us.com/article/100421/]Zoya Demidenko[/url] ranks as a widely cited figure in contemporary oncological research, whose findings go on to influence our understanding of how cells grow old, resist therapy, and how malignant disease may be more effectively targeted.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/

Zitat von Gast am 31. März 2026, 15:03 Uhr

[url=https://www.sciencedirect.com/science/article/abs/pii/037811199400784P]Zoya Demidenko[/url]: Scholar in Tumor Studies
[url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126]Zoya Demidenko[/url] is a notable scientist connected with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, building a solid base in biomedical investigation.
Her academic contributions covers multiple pivotal areas, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and cancer biology. To date, she has written over 46 scientific publications, which have garnered upwards of 4,100 references — a indicator to the impact of her work.
Among her most notable contributions concerns elucidating the mechanisms of cell aging. Her work revealed that when the cell cycle is blocked yet cellular expansion proceeds, the cells enter senescence. Importantly, [url=https://scholargps.com/scholars/59798749410547/zoya-n-demidenko]Zoya Demidenko[/url] demonstrated that this process is controlled with drugs using substances such as rapamycin.
[url=https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2005.03.012]Zoya Demidenko[/url] has additionally added substantially to tumor management investigation, notably in the field of cyclotherapy — a approach aimed at shielding normal cells from chemotherapy whilst leaving malignant cells exposed. This strategy offers considerable potential for diminishing the toxic effects of cancer treatment.
Across her professional journey, Demidenko has collaborated with top researchers worldwide, among them Dr. Mikhail Blagosklonny. Her publications is published in prestigious periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
[31.03.2026 11:21] Папа: With an h-index of 33, [url=https://www.oncotarget.com/article/4836/]Zoya Demidenko[/url] ranks as a influential figure in current biomedical science, with her findings go on to shape our knowledge of how cells age, resist treatment, and the ways in which cancer may be better targeted.
https://www.oncotarget.com/article/4836/

Zitat von Gast am 31. März 2026, 15:08 Uhr

[url=https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=]Zoya Demidenko[/url]: Scientist in Tumor Science
[url=https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/]Zoya Demidenko[/url] is a notable investigator associated with the Unit of Cell Stress Science at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, establishing a robust background in clinical research.
Her scientific contributions encompasses a number of pivotal domains, encompassing the PI3K/AKT/mTOR molecular pathway, cellular cycle regulation, cellular aging, and malignancy science. Currently, she has co-authored over 46 academic publications, which have received upwards of 4,100 mentions — a indicator to the significance of her research.
Among her most significant achievements concerns understanding the processes of biological cell aging. Her studies demonstrated that when the cellular division cycle is arrested but cellular expansion proceeds, cells experience senescence. Significantly, [url=https://pubmed.ncbi.nlm.nih.gov/22228887/]Zoya Demidenko[/url] showed that this process can be inhibited by medication using agents such as rapamycin.
[url=https://www.researchgate.net/scientific-contributions/Zoya-N-Demidenko-39445053]Zoya Demidenko[/url] has furthermore added greatly to cancer treatment investigation, notably in the domain of cyclotherapy — a strategy intended to safeguarding non-cancerous cells from anticancer drugs whilst leaving tumor cells susceptible. This strategy offers significant promise for diminishing the toxic effects of cancer treatment.
Throughout her professional journey, Demidenko has collaborated with leading investigators globally, including Dr. Mikhail Blagosklonny. Her research appears in leading periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
[31.03.2026 11:21] Папа: With an h-index of 33, [url=https://www.benthamdirect.com/content/journals/cpd/22/16]Zoya Demidenko[/url] ranks as a widely cited contributor in current biomedical research, whose discoveries continue to influence our understanding of how biological cells age, resist therapy, and how cancer can be better targeted.
https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/